About this Journal Submit a Manuscript Table of Contents
ISRN Oncology
Volume 2013 (2013), Article ID 753427, 13 pages
http://dx.doi.org/10.1155/2013/753427
Research Article

Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration

1Immunovaccine Inc., Division of Immunology, 1344 Summer Street, Halifax, NS, Canada B3H 0A8
2Department of Microbiology and Immunology, Dalhousie University, 5850 College Street, Halifax, NS, Canada B3H 4R2

Received 15 January 2013; Accepted 6 February 2013

Academic Editors: T. T. Trangas and Y. Yamamoto

Copyright © 2013 Mohan Karkada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. King, J. Waxman, and H. Stauss, “Advances in tumour immunotherapy,” QJM, vol. 101, no. 9, pp. 675–683, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. O. J. Finn, “Molecular origins of cancer: cancer immunology,” The New England Journal of Medicine, vol. 358, no. 25, pp. 2704–2715, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Pejawar-Gaddy and O. J. Finn, “Cancer vaccines: accomplishments and challenges,” Critical Reviews in Oncology/Hematology, vol. 67, no. 2, pp. 93–102, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Sasada, N. Komatsu, S. Suekane, A. Yamada, M. Noguchi, and K. Itoh, “Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines,” European Journal of Cancer, vol. 46, no. 9, pp. 1514–1519, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. S. H. van der Burg, M. S. Bijker, M. J. P. Welters, R. Offringa, and C. J. M. Melief, “Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy,” Advanced Drug Delivery Reviews, vol. 58, no. 8, pp. 916–930, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. A. Rosenberg, J. C. Yang, and N. P. Restifo, “Cancer immunotherapy: moving beyond current vaccines,” Nature Medicine, vol. 10, no. 9, pp. 909–915, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Lanca and B. Silva-Santos, “The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy,” Oncoimmunology, vol. 1, no. 5, pp. 717–725, 2012. View at Publisher · View at Google Scholar
  8. M. Beyer and J. L. Schultze, “Regulatory T cells in cancer,” Blood, vol. 108, no. 3, pp. 804–811, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. T. J. Curiel, “Regulatory T cells and treatment of cancer,” Current Opinion in Immunology, vol. 20, no. 2, pp. 241–246, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. J. Piersma, M. J. P. Welters, and S. H. van der Burg, “Tumor-specific regulatory T cells in cancer patients,” Human Immunology, vol. 69, no. 4-5, pp. 241–249, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Nagaraj and D. I. Gabrilovich, “Tumor escape mechanism governed by myeloid-derived suppressor cells,” Cancer Research, vol. 68, no. 8, pp. 2561–2563, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Ostrand-Rosenberg and P. Sinha, “Myeloid-derived suppressor cells: linking inflammation and cancer,” Journal of Immunology, vol. 182, no. 8, pp. 4499–4506, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. E. Talmadge, “Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy,” Clinical Cancer Research, vol. 13, no. 18, part 1, pp. 5243–5248, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Lizée, L. G. Radvanyi, W. W. Overwijk, and P. Hwu, “Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms,” Clinical Cancer Research, vol. 12, no. 16, pp. 4794–4803, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Liu, J. Nash, C. Runowicz, H. Swede, R. Stevens, and Z. Li, “Ovarian cancer immunotherapy: opportunities, progresses and challenges,” Journal of Hematology and Oncology, vol. 3, article 7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Pagès, A. Berger, M. Camus et al., “Effector memory T cells, early metastasis, and survival in colorectal cancer,” The New England Journal of Medicine, vol. 353, no. 25, pp. 2654–2666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Daftarian, M. Mansour, A. C. Benoit et al., “Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion,” Vaccine, vol. 24, no. 24, pp. 5235–5244, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. P. M. Daftarian, M. Mansour, B. Pohajdak et al., “Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides,” Journal of Translational Medicine, vol. 5, article 26, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Mansour, B. Pohajdak, W. M. Kast et al., “Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax,” Journal of Translational Medicine, vol. 5, article 20, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. N. L. Berinstein, M. Karkada, M. A. Morse et al., “First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients,” Journal of Translational Medicine, vol. 10, no. 1, article 156, 2012. View at Publisher · View at Google Scholar
  21. M. Karkada, G. M. Weir, T. Quinton et al., “A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not treg/tr1-type responses,” Journal of Immunotherapy, vol. 33, no. 3, pp. 250–261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Ramakrishna, M. M. Ross, M. Petersson et al., “Naturally occuring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells,” International Immunology, vol. 15, no. 6, pp. 751–763, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. C. L. Slingluff Jr., G. Yamshchikov, P. Neese et al., “Phase I trial of a melanoma vaccine with gp100280-288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes,” Clinical Cancer Research, vol. 7, no. 10, pp. 3012–3024, 2001. View at Scopus
  24. R. Wang, Q. Wan, L. Kozhaya, H. Fujii, and D. Unutmaz, “Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression,” PLoS One, vol. 3, no. 7, Article ID e2705, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. V. Appay, D. C. Douek, and D. A. Price, “CD8+ T cell efficacy in vaccination and disease,” Nature Medicine, vol. 14, no. 6, pp. 623–628, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. T. L. Whiteside, “The tumor microenvironment and its role in promoting tumor growth,” Oncogene, vol. 27, no. 45, pp. 5904–5912, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Kobayashi and E. Celis, “Peptide epitope identification for tumor-reactive CD4 T cells,” Current Opinion in Immunology, vol. 20, no. 2, pp. 221–227, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. P. R. Dunbar, C. L. Smith, D. Chao et al., “A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response,” Journal of Immunology, vol. 165, no. 11, pp. 6644–6652, 2000. View at Scopus
  29. E. Sato, S. H. Olson, J. Ahn et al., “Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 51, pp. 18538–18543, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Vence, A. K. Palucka, J. W. Fay et al., “Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 52, pp. 20884–20889, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Y. Wang, D. A. Lee, G. Peng et al., “Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy,” Immunity, vol. 20, no. 1, pp. 107–118, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Zhou, C. G. Drake, and H. I. Levitsky, “Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines,” Blood, vol. 107, no. 2, pp. 628–636, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. S. H. van der Burg, S. J. Piersma, A. de Jong et al., “Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 29, pp. 12087–12092, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. P. Welters, G. G. Kenter, S. J. Piersma et al., “Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine,” Clinical Cancer Research, vol. 14, no. 1, pp. 178–187, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Dolcetti, E. Peranzoni, S. Ugel et al., “Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF,” European Journal of Immunology, vol. 40, no. 1, pp. 22–35, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Q. Tran, J. Andersson, R. Wang, H. Ramsey, D. Unutmaz, and E. M. Shevach, “GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3+ regulatory T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 32, pp. 13445–13450, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. J. M. Haverkamp, S. A. Crist, B. D. Elzey, C. Cimen, and T. L. Ratliff, “In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site,” European Journal of Immunology, vol. 41, no. 3, pp. 749–759, 2011. View at Publisher · View at Google Scholar · View at Scopus